Precision radiation may boost hormone therapy for advanced prostate cancer

This study tests whether adding precisely targeted radiation to standard hormone therapy helps men with metastatic hormone-sensitive prostate cancer. All participants first receive six months of darolutamide plus androgen deprivation therapy. Those whose cancer has not progressed and still shows active spots on a special scan (PSMA PET/CT) are then randomly assigned to continue hormone therapy alone or to also receive stereotactic body radiotherapy (SBRT) to those active spots. The goal is to see if the combination extends the time without cancer growth on scans or death.